Significant Presence at 2004 ADA Meeting
17 abstracts accepted
- 8 related to exenatide
- 6 related to SYMLIN®
- 3 related to other pipeline programs
Three corporate sponsored symposia
- Two jointly sponsored with Eli Lilly and Company
Detailed exenatide Phase 3 pivotal results being presented